Highest-materiality recent filing
Certara stockholders elect directors, ratify auditor, approve say-on-pay
All three Class III directors elected: Bedi 121.7M for, McLean 99.9M for (22.9M withheld), Resnick 121.7M for.
Certara Q1 revenue $106.9M (+1%), net loss $8.8M; divests Regulatory Writing for $85M cash
Revenue $106.9M (+1% YoY); software revenue $49.7M (+7%), services revenue $57.2M (-4%).
Certara sells Regulatory & Medical Writing business to Veristat for up to $135M
Cash consideration of $100M plus up to $35M earn-out based on future performance.
Director Cynthia Collins resigns from Certara board, effective May 14, 2026
Cynthia Collins notified her resignation as Class II director and Audit Committee member, effective at the 2026 annual meeting.
Certara Q4 revenue $103.6M (+3%), net loss $5.9M; appoints Jon Resnick CEO; FY26 rev growth 0-4%
Q4 2025 revenue $103.6M (+3% YoY); software revenue $46.4M (+10%), services $57.3M (-1%).
Certara appoints Jon Resnick as CEO effective Jan 1, 2026; Feehery departs Dec 31
Jon Resnick, former IQVIA US/Canada President, named CEO effective Jan 1, 2026; William Feehery steps down Dec 31, 2025.
Certara Q3 2025 revenue $104.6M (+10% YoY); net income $1.5M vs loss; guidance raised
Revenue $104.6M, +10% YoY; software $43.8M (+22%), services $60.8M (+3%).
Certara refinances $296.25M term loans at lower interest rates
Sixth Amendment reduces margin on term loans to SOFR+2.75% or ABR+1.75%.
Certara Q2 2025 revenue $104.6M (+12% YoY); net loss narrows to $2.0M; reiterates FY guidance
Revenue $104.6M (+12% YoY); software revenue $46.7M (+22%), services $57.9M (+5%).
Certara shareholders elect four Class II directors, ratify auditor, approve say-on-pay
Directors elected: Eran Broshy (101.4M for, 44.5M withheld), Cynthia Collins (135.1M for), John Reynders (145.5M for), Matthew Walsh (131.7M for).
Certara Q1 2025 revenue up 10% to $106M; net income positive vs year-ago loss
Revenue $106.0M (+10% YoY); software rev $46.4M (+18%), services $59.6M (+4%).
Certara reports Q1 preliminary revenue up 10% to $106M; $100M buyback authorized
Preliminary Q1 revenue $106.0M (+10% YoY); software revenue $46.4M (+18%), services $59.6M (+4%).
Certara President Patrick F. Smith steps down, moves to senior advisory role
Dr. Patrick F. Smith stepped down as President, Certara Drug Development Solutions, effective March 3, 2025.
Certara Q4 revenue +14% to $100.4M; net income turns positive; guides 2025 margins
Q4 revenue $100.4M (+14% YoY); software rev $42.3M (+26%), services $58.1M (+7%).
Certara reports preliminary Q4 revenue $99.7M (+13% YoY); FY revenue $384.4M (+8%)
Q4 revenue $99.7M vs $88.0M YoY; software +24% to $41.6M, services +7% to $58.1M.
Certara Q3 rev $94.8M (+11% YoY); net loss narrows to $1.4M; guides FY24
Revenue $94.8M (+11% YoY); software rev $35.9M (+15%), services rev $58.9M (+9%).
Certara appoints Dr. John V. W. Reynders to Board of Directors, effective Oct 16, 2024
Dr. Reynders appointed as Class II director and Audit Committee member, effective immediately.
Certara Q2 2024 revenue $93.3M (+3% YoY); net loss $12.6M vs profit prior year
Total revenue $93.3M, up 3% YoY; software revenue $38.2M (+13%), services revenue $55.1M (-3%).
Certara amends bylaws to remove former majority stockholder provisions
On July 17, 2024, Board approved amended and restated Bylaws, effective same day.
Certara signs definitive agreement to acquire Chemaxon; reiterates 2024 guidance
Definitive agreement to acquire Chemaxon, a cheminformatics software provider; no deal value disclosed.
Certara refinances credit facility; extends term loan maturity to 2031, revolver to 2029
Total new term loans of $300M (including $5M incremental) refinance existing debt and fund general corporate purposes.
Certara shareholders elect directors, approve charter amendments, ratify auditor at annual meeting
Elected Class I directors: Cashman (97.7M for), Killefer (116.4M), Spaight (134.1M); all supported.
Certara Q1 revenue $96.7M +7% YoY; net loss $4.7M, reiterates FY guidance
Revenue $96.7M (+7% YoY); software rev $39.3M (+19%), services $57.3M (flat).
On March 5, 2025, Certara, Inc. (the “Company”) announced that Dr. Patrick F. Smith, President, Certara Drug Development Solutions, stepped down from that role as of March 3, 2025, but will remain employed by the Company in a senior advisory and scientific role.
On October 16, 2024, the Board of Directors (the “Board”) of Certara, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, voted to appoint Dr. John V. W. Reynders as a Class II director of the Board and a member of the Audit Committee of the Board, effective immediately.
Max materiality 0.75 · Median 0.65 · Most common event earnings